{"denoms":[{"counts":[{"groupId":"BG000","value":"57"},{"groupId":"BG001","value":"54"},{"groupId":"BG002","value":"111"}],"units":"Participants"}],"groups":[{"description":"One week of treatment with HC3 followed by 3 weeks of no treatment. The standard intensive consolidation chemotherapy course HC3 includes dexamethasone (10 mg/m\\^2/day IV on Days 1-6), vincrisitne (1.5 mg/m\\^2/day IV on Days 1 and 6), daunorubicin (30 mg/m\\^2 IV over 24 hours on Day 5), methotrexate (1 g/m\\^2 IV over 36 hours on Day 1), ifosfamide (800 mg/m\\^2 IV for 1 hour on Days 2-4), and pegylated \\[PEG\\]-asparaginase (1000 U/m\\^2 IV for 2 hours or IM on Day 6) or, if allergic, erwinia-asparaginase (20,000 units/m\\^2 IV or IM every 48 hours for a total of 6 doses).","id":"BG000","title":"HC3 Chemotherapy"},{"description":"One 4-week cycle of blinatumomab 15 μg/m\\^2/day as a continuous intravenous infusion (CIVI).","id":"BG001","title":"Blinatumomab"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"4.3","value":"6.6"},{"groupId":"BG001","spread":"4.4","value":"7.3"},{"groupId":"BG002","spread":"4.4","value":"7.0"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"34"},{"groupId":"BG001","value":"24"},{"groupId":"BG002","value":"58"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"23"},{"groupId":"BG001","value":"30"},{"groupId":"BG002","value":"53"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"4"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"54"},{"groupId":"BG001","value":"53"},{"groupId":"BG002","value":"107"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"46"},{"groupId":"BG001","value":"50"},{"groupId":"BG002","value":"96"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"8"}],"title":"Other, Not Specified"},{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"4"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"3"}],"title":"Black or African American"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"41"},{"groupId":"BG001","value":"39"},{"groupId":"BG002","value":"80"}],"title":"1 to 9 years"},{"measurements":[{"groupId":"BG000","value":"16"},{"groupId":"BG001","value":"15"},{"groupId":"BG002","value":"31"}],"title":"Other (< 1 year and > 9 years)"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Stratification Factor: Age Category","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"17"},{"groupId":"BG001","value":"15"},{"groupId":"BG002","value":"32"}]}],"title":"M1 Marrow + MRD level ≥ 10^-3"},{"categories":[{"measurements":[{"groupId":"BG000","value":"36"},{"groupId":"BG001","value":"35"},{"groupId":"BG002","value":"71"}]}],"title":"M1 Marrow + MRD level < 10^-3"},{"categories":[{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"8"}]}],"title":"M2 Marrow"}],"description":"M1: representative bone marrow aspirate or biopsy with blasts \\< 5%, with satisfactory cellularity and with regenerating hematopoiesis; M2: representative bone marrow aspirate or biopsy with ≥ 5% and \\< 25% blasts; MRD=minimal residual disease levels ≥ 10\\^-3 or \\< 10\\^-3, by polymerase chain reaction (PCR) or flow cytometry.","paramType":"NUMBER","title":"Stratification Factor: Marrow/Minimal Residual Disease (MRD)","unitOfMeasure":"participants"}],"populationDescription":"The FAS included all randomized participants analyzed according to their randomized treatment assignment, regardless of the treatment received."}